Healthcare
NEO Stock Analysis
NeoGenomics, Inc. · current price $18.05 (-3.19% today)
Top-tier setup — +14% 30-day momentum. Momentum, fundamentals and macro indicators are aligned.
★★★★★
Top Tier
NEO Stock AnalysisNeoGenomics, Inc. · current price $18.05 (-3.19% today)
Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.
Reading NEO’s price and volume history…
Checking the areas that decide this thesis…
AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.
Reading NEO’s filings…
NeoGenomics, Inc. (NEO) currently has a TickerMover Quant Score of 70/100, rated ★★★★★ Top Tier. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.
TickerMover does not give buy or sell recommendations. NEO scores 70/100 (★★★★★ Top Tier) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.
NEO's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.
Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.
Open the dashboard for NEO →
